Recursion Pharmaceuticals, an emerging biotechnology company that combines innovative biological science with machine learning techniques to discover treatments for rare genetic diseases, today announced that Yoshua Bengio will be joining the company as a scientific advisor. In this role, Bengio will further Recursion’s machine learning advancements in drug discovery through his expertise in deep learning, while also helping to grow the Recursion team to drive these advancements.
Recursion conducts image-based biology experiments at scale to continuously generate one of the world’s largest high-resolution microscopy datasets. The company expects to produce tens of millions of images in the coming year, each designed with the goal of discovering treatments for rare genetic diseases and other disorders. As a preeminent expert in artificial intelligence and machine learning, Bengio is considered one of the fathers of deep learning, dating back to his research on neural networks and machine learning, as early as the 1980s.
“I and some of my colleagues recognized the potential for neural networks in the 1980s. The explosion of data sizes and computational power along with progress in algorithms in recent years has placed neural networks back at the top of machine learning and artificial intelligence research agendas,” said Yoshua Bengio. “The distinguishing feature of deep learning is the ability to build many layers of increasingly abstract non-linear representations from multiple, heterogeneous data sources. In biology, this means we can now answer questions that were previously intractable by applying deep learning to Recursion’s huge dataset of high-resolution cellular images, coupled with existing biological and chemical data. In so doing we hope to, among many things, rapidly discover many novel therapies for rare genetic diseases.”
Bengio serves as a professor in the Department of Computer Science and Operations Research at the Montreal Institute for Learning Algorithms at the University of Montreal in Canada. As one of the foremost experts on the subject, he is also a Canada Research Chair in Statistical Learning Algorithms. Last year, Bengio co-founded an AI-first company, Element AI, which spins off applications of AI across economic sectors.
Recursion has developed a set of computational and experimental methods that allow it to answer a huge diversity of biological questions rapidly, efficiently and in parallel using the images it produces. Using a combination of machine vision and feature extraction methods, together with cutting edge techniques and powerful deep learning methods, Recursion automates understanding and analysis of these questions from images of cells.
"At Recursion, we recognized early on the significance and potential of applying computer science to advance drug discovery," said Blake Borgeson, Ph.D., co-founder and CTO of Recursion Pharmaceuticals. "Yoshua is the ideal advisor to help Recursion further develop our deep learning approaches and drive advances in biology research with a breadth, efficiency and accuracy that only five years ago would have seemed impossible."
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, artificial intelligence, machine learning, and in vivo validation capabilities with a highly cross-functional team to discover novel medicines and expand our collective understanding of biology. Recursion’s rich, relatable database of 4 petabytes of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. Recursion is proudly headquartered in Salt Lake City. Learn more at www.recursionpharma.com or connect on www.recursionpharma.com, or connect on Twitter, Facebook, and LinkedIn.